Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating income | -$8.56M | -$14.7M | -$28.5M | -$30.0M | -$30.4M | -$19.4M |
| Net income | -$8.56M | -$14.7M | -$28.5M | -$30.0M | -$30.4M | -$19.4M |
| EPS (diluted) | -$3.02 | -$1.47 | -$1.36 | -$1.00 | -$17.05 | -$4.44 |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$7.13M | -$13.5M | -$24.1M | -$23.3M | -$24.1M | -$12.7M |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $18.1M | $37.3M | $18.4M | $21.5M | $11.4M | $27.3M |
| Total assets | $20.9M | $42.2M | $33.0M | $33.7M | $20.9M | $32.3M |
| Total liabilities | $2.59M | $4.04M | $10.3M | $8.77M | $6.47M | $4.72M |
| Shareholders' equity | -$16.6M | -$38.2M | $22.7M | $24.9M | $14.5M | $27.6M |
| Retained earnings | -$18.0M | -$32.7M | -$61.2M | -$91.2M | -$122M | -$141M |
| Shares (wtd avg diluted) | 3.76M | 9.97M | 21.0M | 29.9M | 1.78M | 4.37M |
Every figure is extracted from IN8BIO, INC.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.